Amyotrophic lateral sclerosis (ALS) patients not eligible to participate in clinical trials of pridopidine — a small molecule developed by Prilenia Therapeutics to slow disease progression in ALS — will soon be able to receive the experimental therapy via an expanded access program (EAP). EAPs, also known…

Cytokinetics is calling for proposals from patient advocacy organizations focused on amyotrophic lateral sclerosis (ALS) and cardiovascular conditions for its 6th annual Communications Grant Program. The 2024 program will award five grants totaling $20,000 each to groups serving the ALS, heart failure, and hypertrophic cardiomyopathy communities. These…

I have a vivid and beautiful memory from a few summers ago, as my late husband, Jeff, and I lived with his ALS. We were spending a day on the water, as we often did. Jeff had lost his voice and most of his ability to walk,…

Remember “MacGyver“? In this TV series from the 1980s and early ’90s, the titular secret agent always found himself in an untenable predicament and used whatever was around him to devise a solution. Whether it was a paper clip, a thumbtack, or a toothpick, MacGyver was able to…

A few weeks ago, I was catching up with a friend of mine. Among other topics, we discussed what I might do for work after my husband, Todd, is gone. He has ALS, is paralyzed, and needs noninvasive ventilation. His lung function is quite poor, and I could…

Takeda has obtained an exclusive, worldwide license to AcuraStem’s investigational therapies targeting the PIKfyve enzyme, including AS-202, a potential treatment for amyotrophic lateral sclerosis (ALS) that ultimately aims to lower toxic TDP-43 protein buildup in nerve cells. While Takeda will be responsible for clinical development,…

Last week I felt sad. I had to unravel a knitting project that had consumed a good part of my summer. “What’s the big deal?” you might ask. Well, the big deal is that living with ALS has me feeling hypersensitive to time. How I spend my time…

Neuralink is recruiting participants — including people with amyotrophic lateral sclerosis (ALS) — for the first-in-human trial of its investigational brain-computer interface, designed to enable individuals with paralysis to control external devices with their thoughts. The U.S. Food and Drug Administration initially cleared the study in May under…

NeuroSense Therapeutics has received key patents in Europe, Japan, and Israel covering the use of PrimeC, its investigational, fixed-dose combination therapy, in treating neurological diseases such as amyotrophic lateral sclerosis (ALS). These patents are valid through 2038 and join others covering Prime C’s use in the…

In a nearly unanimous vote, an advisory committee to the U.S. Food and Drug Administration (FDA) said there’s not enough evidence to support the efficacy of the experimental stem cell therapy NurOwn as a treatment for amyotrophic lateral sclerosis (ALS). The committee voted on a single question in its meeting: “Do…